- The Medicines Co. (MDCO +1.4%) initiated with Buy rating and $50 (27% upside) price target by Chardan Capital.
- Opexa Therapeutics (OPXA +1.9%) initiated with Buy rating and $6 (189% upside) price target by Chardan Capital.
- ISIS Pharmaceuticals (ISIS +2.5%) upgraded to Overweight from Neutral by Piper Jaffray. Price target raised to $80 (44% upside) from $64.
- AbbVie (ABBV +1.4%) upgraded to Overweight from Equal Weight by Morgan Stanley. Price target raised to $73 (15% upside) from $62.
- MannKind (MNKD +1.4%) downgraded to Underperform from Outperform by RBC Capital Markets. Price target lowered to $1 (65% downside risk) from $9.
- Valeant Pharmaceuticals (VRX +4.9%) downgraded to Neutral from Buy by Goldman Sachs. Price target lowered to $122 (48% upside) from $180.